- Grey Matter Neurosciences has selected treatment-resistant depression as the first clinical focus for its focused ultrasound neuromodulation platform. A pilot study in seniors and adults is expected to begin in early 2027.
- The non-invasive platform, based on technology developed by Dr. Kullervo Hynynen’s team at Sunnybrook, targets deep brain structures without surgery, implants, incisions or shaving the patient’s head.
- The company has launched an online registry to support recruitment for the pilot study and future research. Dr. Nir Lipsman of Sunnybrook will lead the clinical study in treatment-resistant depression.
- Grey Matter sees depression as the first step toward broader brain applications. Future research may explore mild cognitive impairment and other neurological disorders linked to aging, expanding access to precise, personalized brain therapies.
Takeaways:
Grey Matter’s focused ultrasound platform aims to offer a non‑invasive option for people whose depression hasn’t improved with medications or therapy, by precisely stimulating deep brain circuits without surgery, implants, or shaving the head. If the pilot study (starting in early 2027) shows meaningful benefit and good tolerability, it could open a new treatment path for older adults and others with treatment‑resistant depression and, over time, expand to conditions like mild cognitive impairment and other age‑related brain disorders.
Source: CA Newswire
